A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Tovorafenib (Primary)
- Indications CNS cancer; Glioma; Neurofibromatoses; Solid tumours
- Focus Adverse reactions
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 13 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2021 According to a Day One Biopharmaceuticals media release, this study is sponsored by the Dana-Farber Cancer Institute.